70 related articles for article (PubMed ID: 7739704)
1. Isotretinoin for juvenile chronic myelogenous leukemia.
Donadieu J
N Engl J Med; 1995 Jun; 332(22):1521. PubMed ID: 7739704
[No Abstract] [Full Text] [Related]
2. Isotretinoin for juvenile chronic myelogenous leukemia.
Pui CH; Aricò M
N Engl J Med; 1995 Jun; 332(22):1520-1; author reply 1521. PubMed ID: 7739703
[No Abstract] [Full Text] [Related]
3. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Lichtman MA
Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919
[TBL] [Abstract][Full Text] [Related]
4. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
[TBL] [Abstract][Full Text] [Related]
5. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Oncogene; 2002 Dec; 21(56):8547-59. PubMed ID: 12476301
[No Abstract] [Full Text] [Related]
6. Is another bcr-abl inhibitor needed for chronic myelogenous leukemia?
Sausville EA
Clin Cancer Res; 2003 Apr; 9(4):1233-4. PubMed ID: 12684388
[No Abstract] [Full Text] [Related]
7. Interferon therapy in chronic myelogenous leukemia.
Guilhot F; Roy L; Guilhot J; Millot F
Hematol Oncol Clin North Am; 2004 Jun; 18(3):585-603, viii. PubMed ID: 15271394
[TBL] [Abstract][Full Text] [Related]
8. Current use of imatinib in the treatment of chronic myeloid leukemia.
O'Dwyer M
Haematologica; 2003 Mar; 88(3):241-4. PubMed ID: 12651257
[No Abstract] [Full Text] [Related]
9. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
10. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Moser AM; Manor E; Narkis G; Kapelushnik J
Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
[TBL] [Abstract][Full Text] [Related]
11. Chronic myelogenous leukemia: the new paradigm.
Winn RJ
J Natl Compr Canc Netw; 2003 Oct; 1(4):455. PubMed ID: 19774737
[No Abstract] [Full Text] [Related]
12. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
Ren R
Nat Rev Cancer; 2005 Mar; 5(3):172-83. PubMed ID: 15719031
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
[TBL] [Abstract][Full Text] [Related]
15. Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now.
Mauro MJ
Haematologica; 2005 Mar; 90(3):291B. PubMed ID: 15749655
[No Abstract] [Full Text] [Related]
16. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
17. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient].
Skórski T
Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203
[TBL] [Abstract][Full Text] [Related]
18. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
19. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Chen R; Gandhi V; Plunkett W
Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
[TBL] [Abstract][Full Text] [Related]
20. Juvenile chronic myelogenous leukemia and cytomegalovirus infection.
Ozsoylu S
Am J Pediatr Hematol Oncol; 1991; 13(4):487. PubMed ID: 1664663
[No Abstract] [Full Text] [Related]
[Next] [New Search]
